

Serum ferritin levels among Hepatitis B Sudanese patients in Khartoum, 2018

Imtithal Backry Abdalwahed, DalDalia.m.Ahmed ,Dr. Alya Ahmad salman

¹Department of Hematology, Faculty of Medical Laboratory Sciences, Al-Neelain University, Khartoum, Sudan
²Department of Histopathology&cytology, Faculty of medical laboratory sciences, Omdurman Ahlia university
³Associated Professor of Hematology, pathology depart, Faculty of Medicine Al-Neelain University, Khartoum, Sudan.

Corresponding Author: Imtithal Backry Abdalwahed

Abstract

Background: Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) which affects the liver. It can cause both acute and chronic infections. Ferritin is a universal intracellular protein that stores iron and releases it in a controlled fashion.

Objective: The purpose of this study was to estimate Serum ferritin levels in hepatitis B virus infected patients and normal Controls among the Sudanese population.

Materials and Methods: Forty samples from patients and forty from controls were evaluated to determine the serum ferritin levels among HBV positive patients. The serum ferritin was determined using Roche E411® chemistry analyzer.

Results: The comparison of serum ferritin levels between normal controls and Hepatitis B positive patients are shown in Table 2. The level of Serum ferritin (mean \pm SD) in Hepatitis B group was 392.78 ± 114.61 while in controls group was 139.60 ± 81.50 . We found that serum ferritin levels in Hepatitis B positive group were significantly higher than controls group ($P = 0.000$).

Conclusion: This study concluded that serum ferritin levels increased in patients with positive Hepatitis B virus.

Keywords: Serum ferritin, Hepatitis, HBV.

Date of Submission: 26-04-2018

Date of acceptance: 14-05-2018

I. Introduction

Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) which affects the liver. It can cause both acute and chronic infections. Many people have no symptoms during the initial infection. Some develop a rapid onset of sickness with vomiting, yellowish skin & mucus membrane, tiredness, dark urine and abdominal pain.[1] Often these symptoms last a few weeks and rarely does the initial infection result in death.[1][2]. In those who get infected around the time of birth 90% develop chronic hepatitis B while less than 10% of those infected after the age of five do.[3] Most of those with chronic disease have no symptoms; however, cirrhosis and liver cancer may eventually develop.[4]

The risk factors of HBV infection are :-alcoholic use, drugs, age (neonate and old) and unsafe sex. Transmission of hepatitis B virus results from exposure to infectious blood or body fluids containing blood during sexual contact,[5] blood transfusions and transfusion with other human blood products,[6] re-use of contaminated needles and syringes,[7] and vertical transmission from mother to child during childbirth.[8] Ferritin is a universal intracellular protein that stores iron and releases it in a controlled fashion. The protein is produced by almost all living organisms, including algae, bacteria, higher plants, and animals. In humans, it acts as a buffer against iron deficiency and iron overload. Ferritin is found in most tissues as a cytosolic protein, but small amounts are secreted into the serum where it functions as an iron carrier. Plasma ferritin is also an indirect marker of the total amount of iron stored in the body, hence serum ferritin is used as a diagnostic test for iron-deficiency anemia (normal range of ferritin; male; $23-336$ ng/ml, female; $11-306$ ng/ml).

Ferritin is a globular protein complex consisting of 24 protein subunits and is the primary intracellular iron-storage protein in both prokaryotes and eukaryotes, keeping iron in a soluble and non-toxic form. Ferritin that is not combined with iron is called apoferritin.

There are however multiple copies of the ferritin genes. The major function of ferritin is clearly to provide a store of iron which may be used for haem synthesis when required. Iron uptake in vitro requires an oxidizing agent, and iron release requires a reducing agent. [9]

II. Materials And Methods

This study is a case-control study, conducted in Khartoum state, Sudan, in the period from May to August 2017. It is included 40 patients with Hepatitis B and 40 healthy as control group.

Blood samples were collected from all subjects in Plain containers for measurement of serum ferritin profile using Roche E411® chemistry analyzer method. The control group consisted of healthy volunteers without a medical history of diseases. This study was approved by ethical committee of the faculty of medical laboratory sciences, Alneelain University, and informed consent was obtained from each participant before sample collection.

Elecsys® technology

ECL (ElectroChemiluminescence) is Roche's technology for immunoassay detection. Based on this technology and combined with well designed, specific and sensitive immunoassays, Elecsys delivers reliable results. The development of ECL immunoassays is based on the use of a ruthenium complex and tripropylamine (TPA). The chemiluminescence reaction for the detection of the reaction complex is initiated by applying a voltage to the sample solution resulting in a precisely controlled reaction. ECL technology can accommodate many immunoassay principles while providing superior performance.

III. Results

This case control study includes 80 participants, 40 of them were Sudanese patients with Hepatitis B and 40 apparently healthy volunteers were included in the study as control group.

Statistical analysis :-

The patients' ages were ranged from 18-50 years (Mean 34). The comparison of serum ferritin levels between normal controls and Hepatitis B patients are shown in Table 2. The level of Serum ferritin (mean ± SD) in Hepatitis B group was 392.78±114.61 while in controls group was 139.60±81.50. We found that serum ferritin levels in Hepatitis B group were significantly higher than controls group (P= 0.000). However, Serum ferritin levels among patients age groups 18-28 Years, 29-39 Years and 40-50 Years were found to be 352.81±120.9, 415.44±88.5 and 426.58±73.6, respectively. There was no significant difference in serum ferritin levels between age groups (P > 0.05). shown in the tables below.

Table (1) distribution of patients according to the age

Age group	Frequency	Percentage (%)
18-28 Years	12	30.0
29-39 Years	23	57.5
40-50 Years	5	12.5
Total	40	100.0

Table (2) mean concentration of S.Ferritin in HBV compared with control group

Group	Mean	P-value
Case	392.78±114.61	0.000
Control	139.60±81.50	0.000





Table (3) Distribution of serum ferritin patient according to age group

Age group	Mean±SD	P-value
18-28 Years	352.81±120.9	0.076
29-39 Years	415.44±88.5	0.081
40-50 Years	426.58±73.6	0.062



IV. Discussion

In a large group of patients with chronic viral Hepatitis , we have shown that more than one third had elevations in serum ferritin levels, Thus, many patients with chronic hepatitis have abnormal results of serum ferritin status tests that are probably clinically significant

The most plausible reason individuals with chronic hepatitis have elevated serum ferritin levels in the absence of increased hepatic iron stores is that the serum levels reflect increased release of iron from damaged liver cells. Because the increase in serum ferritin correlated strongly with increase in serum ferritin correlated strongly with the degree of hepatic injury (as measured by the serum AST activity

Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) which affects the liver. It can cause both acute and chronic infections. Many people have no symptoms during the initial infection. Some develop a rapid onset of sickness with vomiting, yellowish skin& mucus membrane , tiredness, dark urine and abdominal pain.[1] Often these symptoms last a few weeks and rarely does the initial infection result in death.[1][2] . In those who get infected around the time of birth 90% develop chronic hepatitis B while less than 10% of those infected after the age of five do.[3] Most of those with chronic disease have no symptoms; however, cirrhosis and liver cancer may eventually develop.[4]

Hepatic injury and dysfunction can disturb iron homeostasis. Excessive iron deposition in the liver leads to further injuries by triggering hepatocellular necrosis, inflammation , fibrosis and even carcinoma . Many experimental and clinical studies suggest that chronic iron deposition promotes the progression of liver damage and increases the risk of fibrosis, cirrhosis, and hepatocellular carcinoma in chronic hepatitis B patients . Furthermore, some studies suggest that excess iron in the liver may induce adverse effects on patients' response to antiviral therapy for chronic hepatitis

4 (Our study shows that comparison of serum ferritin levels between normal controls and Hepatitis B patients are shown in Table 2. The level of Serum ferritin (mean ± SD) in Hepatitis B group was 392.78±114.61 while in controls group was 139.60±81.50. We found that serum ferritin levels in Hepatitis B group were significantly higher than controls group (P= 0.000). Our study agrees with study done by WeiLin Mao et al ^[18] in China 2015. They found that in HBV-infected patients, serum transferrin levels were lower and serum iron and ferritin were higher compared with both non HBV patients. They conclude that the main cause of iron metabolism disorder in cirrhotic HBV-infected patients is liver injury. Another study by Bayraktar *et al.*^[19] agrees with our study, they reported that serum ferritin levels increased in patients with HBV infection.

V. Conclusion

This study concluded that serum ferritin levels increased in patients with Hepatitis B virus. Accordingly, routine monitoring of serum ferritin, serum iron and other iron-associated parameters during clinical management of chronic HBV infection will be helpful in understanding alterations in iron metabolism in HBV and their influence on further liver injury.

Acknowledgment

Thanks to Hematology Department and Faculty of Medical Laboratory Sciences, Alnelain University, Sudan. And special thanks to my parent, Brothers

References

- [1] "Hepatitis B Fact sheet N°204". who.int. July 2014. Retrieved 4 November 2014.
- [2] Raphael Rubin; David S. Strayer (2008). Rubin's Pathology :clinicopathologic foundations of medicine ; [includes access to online text, cases, images, and audio review questions!] (5. ed.). Philadelphia [u.a.]: Wolters Kluwer/Lippincott Williams & Wilkins. p. 638.
- [3] "Hepatitis B FAQs for the Public — Transmission". U.S. Centers for Disease Control and Prevention (CDC). Retrieved 2011-11-29.
- [4] Chang MH (June 2007). "Hepatitis B virus infection". *Semin Fetal Neonatal Med* 12 (3): 160–167.
- [5] buykasik ,N .S., I. Nadir ,F.E .Akin , B .CAKAL , T Kav .O Erosy and Y Buykasik (2011). (serum iron parameter in cirrhosis and chronic hepataitic ; detailed description Turk J Gastroentrol 22(6):606-611.
- [6] El-Serag HB, Rudolph KL (June 2007). "Hepatocellular carcinoma: epidemiology and molecular carcinogenesis". *Gastroenterology* 132 (7): 2557–76.
- [7] El-Serag HB (22 September 2011). "Hepatocellular carcinoma". *New England Journal of Medicine* 365 (12): 1118–27.
- [8] Gan SI, Devlin SM, Scott-Douglas NW, Burak KW (October 2005). "Lamivudine for the treatment of membranous glomerulopathy secondary to chronic hepatitis B infection". *Canadian journal of gastroenterology = Journal canadien de gastroenterologie* 19 (10): 625–9.
- [9] Locarnini S (2004). "Molecular Virology of Hepatitis B Virus". *Seminars in Liver Disease* 24: 3–10.
- [10] Harrison T (2009). *Desk Encyclopedia of General Virology*. Boston: Academic Press. p. 455.
- [11] Howard CR (1986). "The Biology of Hepadnaviruses". *Journal of General Virology* 67 (7): 1215–1235.
- [12] Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV (Nov–Dec 2004). "Global epidemiology of hepatitis B virus". *Journal of Clinical Gastroenterology* 38 (10 Suppl 3): S158–68.
- [13] Redd JT, Baumbach J, Kohn W, Nainan O, Khristova M, Williams I (May 2007). "Patient-to-patient transmission of hepatitis B virus associated with oral surgery". *J. Infect. Dis.* 195 (9): 1311–4.
- [14] Dienstag JL (2008). "Hepatitis B Virus Infection". *New England Journal of Medicine* 359 (14): 1486–1500.
- [15] Bell SJ, Nguyen T (2009). "The management of hepatitis B" (PDF). *AustPrescr* 23 (4): 99–104.
- [16] Kerkar N (2005). "Hepatitis B in children: complexities in management". *Pediatric transplantation* 9 (5): 685–691.
- [17] Taylor JM (2006). "Hepatitis delta virus". *Virology* 344 (1): 71–76.
- [18] Granier T, Langloisd'Estaintot B, Gallois B, Chevalier JM, Précigoux G, Santambrogio P, Arosio P (January 2003). "Structural description of the active sites of mouse L-chain ferritin at 1.2 Å resolution". *Journal of Biological Inorganic Chemistry*. 8 (1-2): 105–11.
- [19] WeiLin Mao, Ying Hu, YuFeng Lou, YueMei Chen, and JuanWen Zhang. *Eur J GastroenterolHepatol*. 2015 Feb; 27(2): 130–136.

Imtithal Backry Abdalwahed "Serum ferritin levels among Hepatitis B Sudanese patients in Khartoum, 2018". *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, vol. 17, no. 5, 2018, pp 33-36.